Developing targeted nanofibers to treat lung tumors
Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors
['FUNDING_R37'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11051810
This study is testing a new way to help people with metastatic lung tumors by using special tiny fibers that can deliver medicine right to the tumors and boost the effects of radiation therapy, aiming to provide better treatment options for those who currently have limited choices.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11051810 on ClinicalTrials.gov |
What this research studies
This research focuses on creating customized nanofibers that can specifically target and treat metastatic lung tumors, which are often difficult to manage with current therapies. The approach involves using peptide-based nanofibers that can deliver a broad-spectrum antitumor medication directly to the tumors while also enhancing the effects of radiation therapy. By improving drug delivery and retention at the tumor site, this innovative method aims to provide a more effective treatment option for patients with lung metastases. The research seeks to address the urgent need for better therapies in this area, where existing options are limited.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic lung tumors who have limited treatment options.
Not a fit: Patients with primary lung tumors or those who do not have lung metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from metastatic lung tumors, potentially improving their prognosis and quality of life.
How similar studies have performed: While the use of nanotechnology in cancer treatment is an emerging field, this specific approach of using targeted nanofibers for lung metastases is novel and has not been extensively tested in previous studies.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BELLAT, VANESSA — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: BELLAT, VANESSA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer therapy, anticancer activity